EA201390993A1 - Антитела к cd38 - Google Patents

Антитела к cd38

Info

Publication number
EA201390993A1
EA201390993A1 EA201390993A EA201390993A EA201390993A1 EA 201390993 A1 EA201390993 A1 EA 201390993A1 EA 201390993 A EA201390993 A EA 201390993A EA 201390993 A EA201390993 A EA 201390993A EA 201390993 A1 EA201390993 A1 EA 201390993A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
bind
therapeutic
human
pharmaceutical compositions
Prior art date
Application number
EA201390993A
Other languages
English (en)
Other versions
EA029303B1 (ru
Inventor
Кэтлин Энн Элиас
Грегори Ландес
Швета Сингх
Ваутер Корвер
Эндрю Уоллинг Дрэйк
Мэри Хаак-Френдшо
Гиорги Пэл Снелл
Винай Бхаскар
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201390993A1 publication Critical patent/EA201390993A1/ru
Publication of EA029303B1 publication Critical patent/EA029303B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Описаны выделенные антитела, связывающиеся с CD38 человека и CD38 яванского макака. Также приведены фармацевтические композиции, содержащие описанные антитела, терапевтические и диагностические способы использования описанных антител.
EA201390993A 2010-12-30 2011-12-30 Антитела к cd38 EA029303B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061428699P 2010-12-30 2010-12-30
US201161470382P 2011-03-31 2011-03-31
US201161470406P 2011-03-31 2011-03-31
US201161485104P 2011-05-11 2011-05-11
PCT/US2011/068235 WO2012092612A1 (en) 2010-12-30 2011-12-30 Anti-cd38 antibodies

Publications (2)

Publication Number Publication Date
EA201390993A1 true EA201390993A1 (ru) 2013-12-30
EA029303B1 EA029303B1 (ru) 2018-03-30

Family

ID=45498158

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390993A EA029303B1 (ru) 2010-12-30 2011-12-30 Антитела к cd38
EA201791186A EA201791186A1 (ru) 2010-12-30 2011-12-30 Антитела к cd38

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791186A EA201791186A1 (ru) 2010-12-30 2011-12-30 Антитела к cd38

Country Status (38)

Country Link
US (10) US8362211B2 (ru)
EP (6) EP3798231A1 (ru)
JP (10) JP5843884B2 (ru)
KR (5) KR101945002B1 (ru)
CN (3) CN103282383B (ru)
AR (1) AR084747A1 (ru)
AU (3) AU2011351921B2 (ru)
BR (1) BR112013017009B1 (ru)
CA (1) CA2822061C (ru)
CO (1) CO6761368A2 (ru)
CR (1) CR20130313A (ru)
CY (3) CY1122161T1 (ru)
DK (3) DK3284754T3 (ru)
EA (2) EA029303B1 (ru)
EC (1) ECSP13012794A (ru)
ES (3) ES2674175T3 (ru)
GE (1) GEP20166493B (ru)
HK (2) HK1245284A1 (ru)
HR (3) HRP20181176T1 (ru)
HU (3) HUE038535T2 (ru)
IL (1) IL226973A (ru)
JO (2) JOP20210044A1 (ru)
LT (3) LT2658871T (ru)
MA (1) MA34763B1 (ru)
MX (2) MX350903B (ru)
MY (1) MY160499A (ru)
NZ (2) NZ705848A (ru)
PE (1) PE20140247A1 (ru)
PL (3) PL3284754T3 (ru)
PT (3) PT2658871T (ru)
RS (3) RS57494B1 (ru)
SG (1) SG191211A1 (ru)
SI (3) SI3284754T1 (ru)
TR (1) TR201808709T4 (ru)
TW (1) TWI564304B (ru)
UY (1) UY33850A (ru)
WO (2) WO2012092616A1 (ru)
ZA (1) ZA201304696B (ru)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556961B2 (en) 2014-02-28 2020-02-11 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10604580B2 (en) 2014-09-09 2020-03-31 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US10766965B2 (en) 2015-05-20 2020-09-08 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10793630B2 (en) 2014-12-04 2020-10-06 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10800851B2 (en) 2014-02-28 2020-10-13 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11021543B2 (en) 2015-06-24 2021-06-01 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
US11566079B2 (en) 2015-11-03 2023-01-31 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
RU2810953C2 (ru) * 2018-03-28 2024-01-09 Такеда Фармасьютикал Компани Лимитед Подкожное дозирование антител к cd38

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
AU2006301446B2 (en) 2005-10-12 2012-06-07 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
MX350540B (es) 2010-09-27 2017-09-08 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
KR102037541B1 (ko) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2900232B1 (en) 2012-09-25 2017-11-15 MorphoSys AG Combinations and uses thereof
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3800204A1 (en) * 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
PT2992013T (pt) * 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3176185A1 (en) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
US10675352B2 (en) * 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2954414A1 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EA035098B1 (ru) * 2014-07-31 2020-04-27 Санофи Способ лечения рецидивирующей и/или рефрактерной множественной миеломы
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
JP7068825B2 (ja) * 2015-04-08 2022-05-17 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８に結合する抗体治療剤
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
HUE051246T2 (hu) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
MY193727A (en) 2015-06-24 2022-10-27 Janssen Biotech Inc Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
EP3319983A1 (en) 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
EP3858388A1 (en) 2015-09-28 2021-08-04 Regents of the University of Minnesota Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
CA3002664A1 (en) 2015-10-25 2017-05-04 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
CN105546709B (zh) * 2016-02-04 2019-01-04 山东格瑞德集团有限公司 孔板送风布风系统
AU2017226960B2 (en) * 2016-03-04 2024-03-21 Morphosys Ag Clinical assessment of M-protein response in multiple myeloma
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
HRP20231188T1 (hr) 2016-04-13 2024-02-02 Sanofi Trispecifični i/ili trovalentni vezujući proteini
EP3452109A1 (en) * 2016-05-03 2019-03-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Cd31shed as a molecular target for imaging of inflammation
WO2018002181A1 (en) * 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
JP2019521171A (ja) 2016-07-20 2019-07-25 ヒブリジェニクス・エスアー 抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
SG11201903359RA (en) 2016-11-02 2019-05-30 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
JP2020500306A (ja) * 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20190381170A1 (en) * 2017-03-01 2019-12-19 Institute For Rheumatic Diseases Co., Ltd. Prophylactic and/or therapeutic agent for autoimmune disease, and vaccine
PT3443006T (pt) 2017-03-17 2023-10-26 Sanofi Sa Proteínas de ligação triespecíficas e/ou trivalentes
WO2018174274A1 (ja) 2017-03-24 2018-09-27 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
WO2018183376A1 (en) * 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Acvr2a-specific antibody and method of use thereof
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
AU2018280868A1 (en) 2017-06-08 2020-01-02 Black Belt Therapeutics Limited CD38 modulating antibody
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CA3067311A1 (en) * 2017-06-20 2018-12-27 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
DK3538645T3 (da) 2017-06-20 2021-04-19 Inst Curie Immunceller der mangler suv39h1
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
KR20200036860A (ko) * 2017-08-16 2020-04-07 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
EP3668543A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
AU2018348093A1 (en) * 2017-10-10 2020-05-28 Sanofi Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
JP7256197B2 (ja) 2017-11-01 2023-04-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原に特異的な抗体およびキメラ抗原受容体
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
CN111542596A (zh) 2017-11-01 2020-08-14 朱诺治疗学股份有限公司 产生工程化细胞的治疗性组合物的方法
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP2021501587A (ja) 2017-11-03 2021-01-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｄ３８指向性キメラ抗原受容体構築物
CN111918876B (zh) * 2017-11-30 2024-02-02 豪夫迈·罗氏有限公司 抗pd-l1抗体及使用其检测pd-l1的方法
DK3720883T3 (da) * 2017-12-05 2023-07-24 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct T-celler omfattende kimære anti-cd38- og anti-cd138-antigenreceptorer og anvendelser deraf
US20210207080A1 (en) 2017-12-08 2021-07-08 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
AU2018379094A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CA3084445A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN112739715A (zh) * 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
CN112154156A (zh) * 2018-03-28 2020-12-29 武田药品工业株式会社 抗cd38抗体的皮下给药
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021526845A (ja) 2018-07-13 2021-10-11 ゲンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
MX2021001519A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Metodos para valorar acidos nucleicos integrados.
MX2021002531A (es) * 2018-09-11 2021-04-28 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
EP3893841A1 (en) 2018-12-14 2021-10-20 MorphoSys AG Antibody formulations
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
CN113454108A (zh) 2019-01-23 2021-09-28 米伦纽姆医药公司 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白
AR119677A1 (es) 2019-01-23 2022-01-05 Millennium Pharm Inc Dominios de unión anti-cd38
EP3914616A1 (en) * 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
JP2022520811A (ja) 2019-02-15 2022-04-01 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
WO2020187718A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200330593A1 (en) * 2019-03-28 2020-10-22 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
US20200308284A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
US20200316197A1 (en) * 2019-03-28 2020-10-08 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
CA3134612A1 (en) * 2019-03-29 2020-10-08 Sorrento Therapeutics, Inc. Engineered variant antibodies that bind cd38
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3136821A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
CN113993543A (zh) 2019-06-10 2022-01-28 武田药品工业株式会社 使用抗cd38抗体的组合疗法
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
CA3142632A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
US20220251572A1 (en) 2019-07-23 2022-08-11 Mnemo Therapeutics Immune cells defective for suv39h1
CN112538114A (zh) * 2019-09-20 2021-03-23 上海普铭生物科技有限公司 抗人cd38抗体及其应用
US20220387317A1 (en) * 2019-11-07 2022-12-08 Ohio State Innovation Foundation Methods and compositions relating to selective intracellular delivery of cd38 inhibitors
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
IL294453A (en) 2020-01-16 2022-09-01 Genmab As Formulations of cd38 antibodies and uses thereof
EP4110830A1 (en) 2020-02-28 2023-01-04 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
JP2023520771A (ja) 2020-03-26 2023-05-19 シージェン インコーポレイテッド 多発性骨髄腫を処置する方法
BR112022020333A2 (pt) 2020-04-10 2022-11-22 Juno Therapeutics Inc Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
US11684676B2 (en) 2020-05-08 2023-06-27 University Of Southern California Site-specific antibody-drug conjugates by ADP-ribosyl cyclases
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
KR20230074713A (ko) 2020-07-30 2023-05-31 엥스띠뛰 퀴리 Socs1에 결함이 있는 면역 세포
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN116802203A (zh) 2020-11-04 2023-09-22 朱诺治疗学股份有限公司 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
EP4301755A1 (en) 2021-03-03 2024-01-10 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN116997654A (zh) 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
WO2022242892A1 (en) * 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4346912A1 (en) 2021-05-25 2024-04-10 Institut Curie Myeloid cells overexpressing bcl2
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
AU2022320793A1 (en) 2021-07-28 2024-02-01 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023017392A1 (en) 2021-08-13 2023-02-16 3M Innovative Properties Company Antistatic fabric article
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
TW202342520A (zh) 2022-02-18 2023-11-01 美商樂天醫藥生技股份有限公司 抗計畫性死亡配體１（ｐｄ—ｌ１）抗體分子、編碼多核苷酸及使用方法
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024054775A1 (en) * 2022-09-09 2024-03-14 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JPH0684377B1 (ru) 1986-04-17 1994-10-26 Kyowa Hakko Kogyo Kk
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0530225A4 (en) 1990-05-07 1993-09-22 Scripps Clinic And Research Foundation Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6123894A (en) * 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
AU685939B2 (en) 1994-04-22 1998-01-29 Kyowa Hakko Kogyo Co. Ltd. DC-89 derivative
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2002030954A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
BR0114475A (pt) 2000-10-06 2003-12-23 Kyowa Hakko Kogyo Kk Célula para a produção de composição de anticorpo
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1434778A4 (en) 2001-05-31 2005-07-13 Medarex Inc CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US7497862B2 (en) 2001-08-03 2009-03-03 Tyco Healthcare Group Lp Tissue marking apparatus and method
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
ATE516818T1 (de) 2002-07-31 2011-08-15 Seattle Genetics Inc Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DE10246870B3 (de) 2002-10-08 2004-04-29 Renk Aktiengesellschaft Elektro-Hydrodynamische Überlagerungslenkung
CN100526460C (zh) * 2002-11-08 2009-08-12 麒麟医药株式会社 朊病毒蛋白活性降低的转基因有蹄类动物及其用途
CA2506080A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2477765T3 (es) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Agentes de unión al anti-cd70 humanizado y usos de los mismos
US20090123950A1 (en) * 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
JP2009509918A (ja) 2005-08-05 2009-03-12 シンタルガ・ビーブイ トリアゾール含有放出可能なリンカー、これらの共役体、および製造方法
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006301446B2 (en) * 2005-10-12 2012-06-07 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
DK1940789T3 (da) 2005-10-26 2012-03-19 Medarex Inc Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1994000B1 (en) 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
CA2664740C (en) * 2006-09-26 2021-11-16 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2173739B1 (en) 2007-08-01 2013-07-31 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
RU2570559C2 (ru) * 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
US8399630B2 (en) * 2008-08-20 2013-03-19 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2412808B1 (en) 2009-03-25 2016-09-07 Tohoku University Lh-type bispecific antibody
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery
KR20210044218A (ko) * 2018-07-11 2021-04-22 모멘타 파머슈티컬스 인코포레이티드 CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713355B2 (en) 2014-02-28 2023-08-01 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10556961B2 (en) 2014-02-28 2020-02-11 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10800851B2 (en) 2014-02-28 2020-10-13 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10604580B2 (en) 2014-09-09 2020-03-31 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10793630B2 (en) 2014-12-04 2020-10-06 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
US10766965B2 (en) 2015-05-20 2020-09-08 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US11021543B2 (en) 2015-06-24 2021-06-01 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11566079B2 (en) 2015-11-03 2023-01-31 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11708419B2 (en) 2015-11-03 2023-07-25 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11708420B2 (en) 2015-11-03 2023-07-25 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11732051B2 (en) 2015-11-03 2023-08-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
RU2810953C2 (ru) * 2018-03-28 2024-01-09 Такеда Фармасьютикал Компани Лимитед Подкожное дозирование антител к cd38

Also Published As

Publication number Publication date
JP7315598B2 (ja) 2023-07-26
CN113480649A (zh) 2021-10-08
JP2018029581A (ja) 2018-03-01
JP2020022464A (ja) 2020-02-13
JP6425635B2 (ja) 2018-11-21
WO2012092616A1 (en) 2012-07-05
RS57494B1 (sr) 2018-10-31
MX2013007455A (es) 2013-07-22
US20150203587A1 (en) 2015-07-23
US20140155584A1 (en) 2014-06-05
PE20140247A1 (es) 2014-03-12
EP3284755B1 (en) 2020-10-07
DK2658871T3 (en) 2018-08-13
ES2674175T3 (es) 2018-06-27
CA2822061C (en) 2022-10-18
JP6840813B2 (ja) 2021-03-10
CR20130313A (es) 2013-08-09
CY1122161T1 (el) 2020-07-31
EP2658870A1 (en) 2013-11-06
CY1122165T1 (el) 2020-07-31
NZ705848A (en) 2016-07-29
US20230037373A1 (en) 2023-02-09
PL3284754T3 (pl) 2021-04-06
JP2014509187A (ja) 2014-04-17
GEP20166493B (en) 2016-06-27
TR201808709T4 (tr) 2018-07-23
ZA201304696B (en) 2014-09-25
KR20140032963A (ko) 2014-03-17
EA201791186A1 (ru) 2017-10-31
ES2690095T3 (es) 2018-11-19
JP2014509837A (ja) 2014-04-24
KR20190015764A (ko) 2019-02-14
KR102602640B1 (ko) 2023-11-16
JP6563446B2 (ja) 2019-08-21
JP6766233B2 (ja) 2020-10-07
HRP20181245T1 (hr) 2018-10-05
AU2011351921A1 (en) 2013-07-11
US9102744B2 (en) 2015-08-11
US20180066069A1 (en) 2018-03-08
EP3798231A1 (en) 2021-03-31
DK2658870T3 (en) 2018-08-06
KR101945002B1 (ko) 2019-02-07
JP2016034954A (ja) 2016-03-17
MA34763B1 (fr) 2013-12-03
JOP20210044A1 (ar) 2017-06-16
PT3284754T (pt) 2020-12-21
KR102451597B1 (ko) 2022-10-06
TWI564304B (zh) 2017-01-01
TW201247705A (en) 2012-12-01
US20200040105A1 (en) 2020-02-06
SG191211A1 (en) 2013-07-31
JOP20110402B1 (ar) 2021-08-17
SI3284754T1 (sl) 2021-03-31
CN103282383A (zh) 2013-09-04
MX2020012426A (es) 2021-02-18
SI2658871T1 (sl) 2018-11-30
JP5843884B2 (ja) 2016-01-13
US10336833B2 (en) 2019-07-02
HUE052906T2 (hu) 2021-05-28
IL226973A (en) 2016-08-31
BR112013017009B1 (pt) 2022-07-26
HK1245284A1 (zh) 2018-08-24
JP6621447B2 (ja) 2019-12-18
SI2658870T1 (sl) 2018-10-30
EP2658871A1 (en) 2013-11-06
US8362211B2 (en) 2013-01-29
KR20200009142A (ko) 2020-01-29
DK3284754T3 (da) 2020-12-21
LT2658870T (lt) 2018-09-10
EP3789404A1 (en) 2021-03-10
AR084747A1 (es) 2013-06-05
RS61280B1 (sr) 2021-02-26
US11434304B2 (en) 2022-09-06
EP3284754A1 (en) 2018-02-21
CN107365385A (zh) 2017-11-21
CY1123739T1 (el) 2022-03-24
JP2016121139A (ja) 2016-07-07
KR102294213B1 (ko) 2021-08-27
US8926969B2 (en) 2015-01-06
US20130171154A1 (en) 2013-07-04
RS57526B1 (sr) 2018-10-31
US9790285B2 (en) 2017-10-17
PT2658871T (pt) 2018-08-07
HRP20181176T1 (hr) 2018-09-21
US20150291702A1 (en) 2015-10-15
JP7096301B2 (ja) 2022-07-05
LT3284754T (lt) 2021-01-25
EA029303B1 (ru) 2018-03-30
AU2019264573B2 (en) 2021-08-12
UY33850A (es) 2012-07-31
PL2658871T3 (pl) 2018-11-30
AU2019264573A1 (en) 2019-12-05
NZ612272A (en) 2015-04-24
JP6148984B2 (ja) 2017-06-14
JP2021019588A (ja) 2021-02-18
KR20210107892A (ko) 2021-09-01
HK1250735A1 (zh) 2019-01-11
ECSP13012794A (es) 2013-10-31
JP2018019689A (ja) 2018-02-08
US20180016349A1 (en) 2018-01-18
WO2012092612A1 (en) 2012-07-05
JP2021087437A (ja) 2021-06-10
US20200031951A1 (en) 2020-01-30
KR20220139441A (ko) 2022-10-14
HUE038727T2 (hu) 2018-11-28
JP6425644B2 (ja) 2018-11-21
EP3284754B1 (en) 2020-11-04
US9676869B2 (en) 2017-06-13
PT2658870T (pt) 2018-07-03
CN103282383B (zh) 2017-08-29
CO6761368A2 (es) 2013-09-30
AU2011351921B2 (en) 2017-04-13
PL2658870T3 (pl) 2018-11-30
MY160499A (en) 2017-03-15
US20120201827A1 (en) 2012-08-09
JP2019205454A (ja) 2019-12-05
KR102070326B1 (ko) 2020-01-29
EP2658871B1 (en) 2018-05-02
MX350903B (es) 2017-09-25
HUE038535T2 (hu) 2018-10-29
BR112013017009A2 (pt) 2017-07-25
ES2841299T3 (es) 2021-07-08
AU2017204571A1 (en) 2017-07-27
AU2017204571B2 (en) 2019-09-19
EP2658870B1 (en) 2018-04-25
LT2658871T (lt) 2018-09-10
HRP20201996T1 (hr) 2021-02-05
CA2822061A1 (en) 2012-07-05
EP3284755A1 (en) 2018-02-21
US10494444B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
EA201791186A1 (ru) Антитела к cd38
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
EA201400579A1 (ru) Антитела к il-36r
EA201401204A1 (ru) Антитела к il-23p19
EA201201357A1 (ru) Антитела к cd40
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201300530A1 (ru) Антитела к il-23
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201370018A1 (ru) Составы рифаксимина и их применение
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX340295B (es) Anticuerpos monoclonales anti-c-met.
EA201270722A1 (ru) Формы рифаксимина и их применение
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
UA109464C2 (ru) Спироксиндольные антагонисты mdm2
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201390117A1 (ru) Композиция антител к vegfr-3
TN2013000265A1 (en) Anti-cd38 antibodies
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists